Ignite Creation Date:
2025-12-24 @ 7:12 PM
Ignite Modification Date:
2025-12-26 @ 6:03 PM
Study NCT ID:
NCT06093503
Status:
WITHDRAWN
Last Update Posted:
2024-06-26
First Post:
2023-10-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-04-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-04-11
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-17
First Submit QC Date:
None
Study First Post Date:
2023-10-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-24
Last Update Post Date:
2024-06-26
Last Update Post Date Type:
ACTUAL